MaaT033

DRUG4 trials

Sponsors

Maat Pharma, Assistance Publique Hopitaux De Paris, Institut Gustave Roussy, MaaT Pharma

Conditions

ALSAXIAL SPONDYLOARTHRITISAdvanced non-small cell lung cancerAmyotrophic Lateral SclerosisPatients with hematologic malignancies and undergoing allogenic hematopoietic cell transplantation

Phase 1

Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

CompletedNCT05889572

MaaT PharmaALS, Amyotrophic Lateral Sclerosis

Start: 2023-06-08End: 2024-07-22Updated: 2025-06-15

Phase 2

A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications

RecruitingCTIS2022-501831-18-00

Maat PharmaPatients with hematologic malignancies and undergoing allogenic hematopoietic cell transplantation

Start: 2023-09-13Target: 374Updated: 2026-01-19

FMT-SPA - RANDOMIZED DOUBLE BLIND CONTROLLED STUDY ASSESSING THE EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RESISTANT TO CONVENTIONAL TREATMENT

RecruitingCTIS2023-504852-89-00

Assistance Publique Hopitaux De ParisAXIAL SPONDYLOARTHRITIS

Start: 2025-04-07Target: 25Updated: 2025-09-11

A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE2

RecruitingCTIS2024-517018-14-00

Institut Gustave RoussyAdvanced non-small cell lung cancer

Start: 2025-11-17Target: 162Updated: 2025-09-22